Raab, C.; Brugger, S.; Lechner, J.-S.; Barbalho, G.N.; Gratieri, T.; Agarwal, P.; Rupenthal, I.D.; Keck, C.M.
Utilizing an Ex Vivo Skin Penetration Analysis Model for Predicting Ocular Drug Penetration: A Feasibility Study with Curcumin Formulations. Pharmaceutics 2024, 16, 1302.
https://doi.org/10.3390/pharmaceutics16101302
AMA Style
Raab C, Brugger S, Lechner J-S, Barbalho GN, Gratieri T, Agarwal P, Rupenthal ID, Keck CM.
Utilizing an Ex Vivo Skin Penetration Analysis Model for Predicting Ocular Drug Penetration: A Feasibility Study with Curcumin Formulations. Pharmaceutics. 2024; 16(10):1302.
https://doi.org/10.3390/pharmaceutics16101302
Chicago/Turabian Style
Raab, Christian, Stefan Brugger, Jara-Sophie Lechner, Geisa Nascimento Barbalho, Taís Gratieri, Priyanka Agarwal, Ilva D. Rupenthal, and Cornelia M. Keck.
2024. "Utilizing an Ex Vivo Skin Penetration Analysis Model for Predicting Ocular Drug Penetration: A Feasibility Study with Curcumin Formulations" Pharmaceutics 16, no. 10: 1302.
https://doi.org/10.3390/pharmaceutics16101302
APA Style
Raab, C., Brugger, S., Lechner, J.-S., Barbalho, G. N., Gratieri, T., Agarwal, P., Rupenthal, I. D., & Keck, C. M.
(2024). Utilizing an Ex Vivo Skin Penetration Analysis Model for Predicting Ocular Drug Penetration: A Feasibility Study with Curcumin Formulations. Pharmaceutics, 16(10), 1302.
https://doi.org/10.3390/pharmaceutics16101302
